drugset / Trial / NCT02072512
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of goserelin plus fulvestrant 500mg comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and perimenopausal HR+ advanced breast cancer.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-11
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anastrozole | Other / unclassified | 1 mg | Oral |
| Comparator | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Comparator | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |